Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Seth Lederman bought 20,000 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average cost of $1.16 per share, for a total transaction of $23,200.00. Following the acquisition, the chief executive officer now owns 177 shares of the company’s stock, valued at $205.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of TNXP stock opened at $1.13 on Wednesday. The company has a market cap of $1.78 million, a price-to-earnings ratio of 0.00 and a beta of 1.03. The stock has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.03. Tonix Pharmaceuticals Holding Corp has a 12-month low of $1.04 and a 12-month high of $72.40. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 0.01.
Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Friday, November 8th. The company reported ($5.69) EPS for the quarter, missing the consensus estimate of ($4.35) by ($1.34). On average, equities analysts forecast that Tonix Pharmaceuticals Holding Corp will post -24.74 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC raised its position in Tonix Pharmaceuticals by 620.0% in the second quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock worth $89,000 after acquiring an additional 56,516 shares in the last quarter. Vanguard Group Inc. acquired a new stake in Tonix Pharmaceuticals in the second quarter valued at $117,000. Finally, A.R.T. Advisors LLC purchased a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth $42,000. 35.56% of the stock is currently owned by hedge funds and other institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Featured Story: What is basic economics?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.